

PRESS RELEASE

Strasbourg, January 29, 2021 – 7:30 am

BIOSYNEX announces the great success of its capital increase through placement with qualified investors for an amount of €15m

Strasbourg, January 29, 2021 – 7:30 am – BIOSYNEX (FR0011005933/ Mnemonic : ALBIO), a major player in public health, today announces the great success of its capital increase without shareholders' preferential subscription rights for a final amount of € 15 million through an offering to qualified French and international investors (“the Transaction”) carried out by accelerated bookbuilding. The order book was largely covered, based on sustained demand from new and existing institutional investors, totaling € 20.24m.

The Transaction led to the issue of 882,352 new shares with a unit par value of € 0.10, i.e. 9.64% of the Company's current share capital, at a price per share of € 17.00 (issue premium included), for a total amount of €14,999,984 (or 8.79% of the post-transaction share capital of the Company).

Following the Transaction, the Company's share capital now consists of 10,036,337 shares with a par value of €0.10 each. Based on the available cash (€ 11.08 million as of June 30, 2020) and its forecast income and expenses, the amount raised as a result of the Transaction should enable the Company to achieve its strategic objectives and to cover its working capital needs well beyond the next 12 months.

Larry ABENSUR, Chairman and CEO, said on this occasion: « *We would like to thank the long-standing shareholders for having participated in this fundraising which demonstrates their involvement and their confidence in the Company and are delighted to welcome new investors, particularly foreign investors, to BIOSYNEX's share capital..*»

USE OF PROCEEDS

The funds raised will enable the Group to accelerate its development towards new outlets through external growth operations. These external growth operations will aim to complete its range of rapid visual tests with small, rapid, and connected diagnostic equipment.

MAIN CHARACTERISTICS OF THE TRANSACTION

A total number of 882,352 new ordinary shares, with a unit par value of €0.10, were issued to 23 qualified investors, including 9 foreign investors (Europe), within the meaning of article 2 (e) of Regulation (EU) No. 2017/1129 of June 14, 2017, as referred to in 1 ° of Article L.411-2 of the Monetary and Financial Code, in accordance with the 9th resolution of the General Meeting of the Company held on June 8, 2020.

The new shares were issued by decisions of the Board of Directors of January 28, 2021 and of the Chairman and CEO of January 28, 2021, in accordance with the delegation of authority conferred by the 9th resolution approved by the General Meeting of the Company held on June 8, 2020.

The issue price of the new shares was set at €17.00 per share, representing a discount of 17.62% compared to the volume-weighted average of the BIOSYNEX share on the Euronext Growth Paris market of the quoted prices of the last five (5) trading sessions prior to the price being set (ie from January 22 to January 28, 2021), i.e. €20.635, and a discount of 13.27% compared to the BIOSYNEX share closing price on January 28, 2021, i.e. €19.60, in accordance with the decisions of the Board of Directors of January 28, 2021, taken pursuant to the 9th resolution of the General Meeting held on June 8, 2020, which set the maximum authorized discount at 20% of the average weighted prices of the quoted prices of the last five (5) trading sessions preceding the fixing of the price.

BIOSYNEX's share capital will consist of 10,036,337 shares following the settlement-delivery of the capital increase.

To the best of the Company's knowledge, the shareholder base before and after the completion of the Transaction is as follows:

| Actionnaires | Before completion of the Transaction | | | | After completion of the Transaction | | | |
|---------------------------------|--------------------------------------|---------------|-------------------|--------------------|-------------------------------------|----------------|-------------------|--------------------|
| | # of shares | % of capital | #of voting rights | % of voting rights | # of shares | % of capital | #of voting rights | % of voting rights |
| ALA FINANCIERE | 3 694 406 | 40,36% | 5 975 434 | 45,60% | 3 694 406 | 36,81% | 5 975 434 | 42,72% |
| Larry ABENSUR | 187 666 | 2,05% | 348 332 | 2,66% | 187 666 | 1,87% | 348 332 | 2,49% |
| Larry ABENSUR Family | 2 001 | 0,02% | 2 002 | 0,02% | 2 001 | 0,02% | 2 002 | 0,01% |
| Sub total ABENSUR Family | 3 884 073 | 42,43% | 6 325 768 | 48,27% | 3 884 073 | 38,70% | 6 325 768 | 45,23% |
| AJT FINANCIERE | 1 000 138 | 10,93% | 2 000 276 | 15,26% | 1 000 138 | 9,97% | 2 000 276 | 14,30% |
| Thomas LAMY | 144 060 | 1,57% | 288 120 | 2,20% | 144 060 | 1,44% | 288 120 | 2,06% |
| Sub total Thomas LAMY | 1 144 198 | 12,50% | 2 288 396 | 17,46% | 1 144 198 | 11,40% | 2 288 396 | 16,36% |
| AXODEV | 303 061 | 3,31% | 606 122 | 4,63% | 303 061 | 3,02% | 606 122 | 4,33% |
| Thierry PAPER | 60 936 | 0,67% | 121 872 | 0,93% | 60 936 | 0,61% | 121 872 | 0,87% |
| Sub total Thierry PAPER | 363 997 | 3,98% | 727 994 | 5,56% | 363 997 | 3,63% | 727 994 | 5,21% |
| Public | 3 761 717 | 41,09% | 3 761 717 | 28,71% | 4 644 069 | 46,27% | 4 644 069 | 33,20% |
| Total | 9 153 985 | 100% | 13 103 875 | 100% | 10 036 337 | 100,00% | 13 986 227 | 100,00% |

For illustration purposes, the participation of a shareholder holding 1% of the Company's share capital prior to the Transaction will be diminished to 0.91%.

ADMISSION TO TRADING OF NEW SHARES

The new shares will bear dividend rights and will be admitted to trading on the Euronext Growth Paris market under the same ISIN code FR0011005933 - ALBIO. The settlement and delivery of the new shares and their admission to trading on the Euronext Growth Paris market are scheduled for February 2, 2021.

The information presented in this press release is issued at the end of the placement of the shares by accelerated bookbuilding, which is now closed, but remains conditional on the correct execution of the settlement-delivery operations.

Pursuant to the provisions of article L.411-2 of the Monetary and Financial Code and article 1.4 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, the Offer has not given and will not give rise to the preparation of a prospectus subject to the approval of the Autorité des marchés financiers (the "AMF").

RISK FACTORS

The main risk factors associated with the Transaction are listed below:

- The market price of the Company's shares could fluctuate and fall below the subscription price of the new shares issued in the context of the Transaction;
- Due to stock market fluctuations, the volatility and liquidity of the Company's shares could vary significantly;
- Sales of Company shares could occur on the secondary market, after completion of the Transaction and have an unfavorable impact on the Company's share price;
- The Company has not paid dividends during the last three fiscal years.

Detailed information concerning the Company, in particular relating to its activity and its results, appears in the management report of the Company for the financial year ended on December 31, 2019, which can be consulted, as well as the other regulated information and all Company press releases on its website (www.biosynex.com).

TRANSACTION PARTNERS

**Lead Partner and
Bookrunner**

STIFEL

Transaction Advisory

EuroLand
Corporate

Legal Counsel

fieldfisher

**Financial
communication**

cap value
COMMUNICATION POUR VALEURS DE CROISSANCE

Contacts



Larry Abensur
Chairman & CEO
abensur@biosynex.com

EuroLand
Corporate

Julia Bridger
Listing Sponsor
+33 1 44 70 20 84
jbridger@elcorp.com



Gilles Broquelet
Financial communication
+ 33 1 80 81 50 00
gbroquelet@capvalue.fr

About BIOSYNEX

Created in 2005 and based in Illkirch-Graffenstaden in Alsace, a major player in public health with more than 180 employees, the French laboratory BIOSYNEX designs, manufactures and distributes Rapid Diagnostic Tests (RDTs). In their professional version, they offer better medical care for patients thanks to the speed of their results and their ease of use. In their self-test version, they allow the general public to self-monitor various pathologies, thus ensuring better prevention and accelerating the demand for care. Leader on the RDT market in France, BIOSYNEX is the only player to fully control its value chain thanks to its technological platform that can be used in many applications and adapted to different types of users such as laboratories, hospitals, doctors and General public.

More information on www.biosynex.com

Disclaimer

This press release, and the information it contains, does not constitute an offer to sell or subscribe, nor a solicitation of an order to buy or subscribe, for BIOSYNEX shares in any country.

This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) No. 2017/1129 of the European Parliament and of the Council of June 14, 2017 (the "Prospectus Regulation").

In the Member States of the European Economic Area and in the United Kingdom, this communication and any offers which may follow it are addressed exclusively to persons who are "qualified investors" within the meaning of article 2 (e) of Prospectus Regulations.

This press release does not constitute an offer to sell any securities or any solicitation of an offer to buy or subscribe for securities in the United States of America. BIOSYNEX shares, or any other security, may only be offered or sold in the United States of America following registration under the US Securities Act of 1933, as amended (the "Securities Act"), or as part of an exemption from this registration obligation, it being specified that the shares of the company BIOSYNEX have not been and will not be registered under the US Securities Act. BIOSYNEX does not intend to register the offering in whole or in part in the United States of America or to make a public offering in the United States of America.

Regarding the United Kingdom, the distribution of this press release is not made by and has not been approved by an authorized person within the meaning of Article 21 (1) of the Financial Services and Markets Act 2000. Accordingly, the press release is addressed only to persons who (i) are investment professionals within the meaning of section 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as currently in force, hereinafter the "Financial Promotion Order"), (ii) are referred to in article 49 (2) (a) to (d) ("high net worth companies, unincorporated associations etc. ") Of the Financial Promotion Order, (iii) are outside the United Kingdom (all such persons being together referred to as the "Qualified Persons"). This press release is addressed only to Authorized Persons and may not be used by anyone other than an Authorized Person.

This press release contains information on BIOSYNEX's objectives as well as forward-looking statements. This information is not historical data and should not be interpreted as a guarantee that the facts and data stated will occur. This information is based on data, assumptions and estimates considered reasonable by BIOSYNEX. The latter operates in a competitive and rapidly changing

This press release may not be released, published, or distributed, directly or indirectly, in the United States, Canada, Japan or Australia. This press release does not constitute an offer and is provided for informational purposes only.



environment. It is therefore not in a position to anticipate all the risks, uncertainties or other factors likely to affect its activity, their potential impact on its activity or to what extent the materialization of a risk or a combination of risks could have results that are significantly different from those mentioned in any forward-looking information. This information is given only as of the date of this press release. BIOSYNEX makes no commitment to publish updates to this information or the assumptions on which it is based, except for any legal or regulatory obligation that may apply to it.

The distribution of this press release may, in certain countries, be subject to specific regulations. Accordingly, persons physically present in these countries and in which the press release is disseminated, published, or distributed must inform themselves and comply with these laws and regulations.

This press release must not be published, transmitted, or distributed, directly or indirectly, in the territory of the United States of America, Australia, Canada or Japan.

This press release may not be released, published, or distributed, directly or indirectly, in the United States, Canada, Japan or Australia. This press release does not constitute an offer and is provided for informational purposes only.